131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
Public ClinicalTrials.gov record NCT00114309. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.
Study identification
- NCT ID
- NCT00114309
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2004
- Primary completion
- Feb 28, 2009
- Completion
- Jul 31, 2009
- Last update posted
- Apr 2, 2009
2004 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3410 | — |
| City of Hope | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Johns Hopkins Medical Center | Baltimore | Maryland | 21287 | — |
| Tufts-New England Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Lacks Cancer Center at St. Mary's Health Care | Grand Rapids | Michigan | 49503 | — |
| St. Louis Hospital | St Louis | Missouri | 63110 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Carolina Neurosurgery and Spine | Charlotte | North Carolina | 28204 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75246 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Washington | Seattle | Washington | 98195-6470 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00114309, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2009 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00114309 live on ClinicalTrials.gov.